Updated:
MAIA Biotechnology
Vlad Vitoc's MAIA Biotechnology targets cancer via telomere biology — a clinical-stage biotech advancing THIO in Phase 2 lung cancer trials.
MAIA Biotechnology
MAIA Biotechnology was established in Chicago in 2018 by CEO Vlad Vitoc, a serial entrepreneur with prior ventures in oncology-focused drug development. The company operates as a clinical-stage biopharmaceutical firm rather than a family office or fund manager, raising capital through public equity markets — it listed on the NYSE American in 2022 under the ticker MAIA — and deploying it toward proprietary research programs. The underlying scientific thesis centers on the enzyme telomerase, which enables cancer cells to divide indefinitely; MAIA's therapeutic candidates aim to disable this mechanism. The company's lead asset, THIO (6-thio-dG), is a telomere-targeting agent being tested in a Phase 2 clinical trial for advanced non-small cell lung cancer, with enrollment underway at multiple U.S. and European sites as of 2025. Beyond THIO, MAIA is developing a second-generation telomere-targeting program and an immunotherapy platform, covering modalities from small molecules to biologics. The geographic footprint spans trial sites in the United States, Europe, and Australia. Manufacturing and clinical operations are managed through a lean internal team and contract research organizations. As a micro-cap biotech, MAIA reported approximately $9 million in cash and equivalents at the end of the fourth quarter of 2023, funding runway-extension milestones. The firm maintains a small headcount concentrated in Chicago and outsources significant R&D functions — a capital-efficient model typical of preclinical and early clinical-stage biotechs. Adjacent vehicles include standard equity incentive plans for executives and scientific collaborators, but no separate philanthropic foundation or investor club. In August 2024, the company presented updated Phase 2 data at the IASLC World Conference on Lung Cancer, reinforcing the molecule's observed safety profile and preliminary efficacy signals. MAIA's structural distinction lies in its focus on telomere biology as a therapeutic target — a narrow field with few direct competitors — and its public-company status, which provides retail and institutional investors a liquid path into early-stage oncology research. The firm lacks the perpetual capital of a family office or the deployment pace of a venture fund, instead advancing a single pipeline through milestone-driven financing rounds and grant support from the National Cancer Institute.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chicago
Corporate office
Chicago, IL, United States
Principals
Vlad Vitoc
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at MAIA Biotechnology?
MAIA Biotechnology is an operating biopharmaceutical company, not an investment firm. Capital allocation decisions rest with CEO Vlad Vitoc and the board of directors, who oversee the public company's budget and clinical-trial financing strategy. The firm's spending is directed almost entirely toward R&D, with no external fund commitments or LP-driven investment mandates.
How does MAIA Biotechnology source its deal flow or pipeline assets?
MAIA does not source deals in the traditional investment sense; its pipeline originates from in-house research into telomere-targeting mechanisms. The company's scientific team identifies and validates new chemical entities targeting telomerase, filing its own patents and advancing leads toward Investigational New Drug applications. Occasional in-licensing of complementary technologies supplements the internal discovery engine.
Is MAIA Biotechnology structured as a family office or a venture firm?
Neither. MAIA is a publicly traded clinical-stage biotech corporation listed on the NYSE American since 2022. It raises capital through equity offerings rather than managing a single family's wealth or investing in third-party startups. Its sole focus is developing anticancer therapies from its own research.
What investment stages or asset classes does MAIA target?
MAIA is not an investment manager and does not deploy capital into fund commitments, direct co-investments, or real assets. The firm's balance sheet is allocated to clinical development, manufacturing, and intellectual property related to its oncology programs. External collaborations are structured as research agreements rather than financial investments.
Where does MAIA Biotechnology's funding come from?
Funding comes from public equity raises, including its 2022 initial public offering and subsequent at-the-market facilities, supplemented by National Cancer Institute grants and potential licensing revenue. The company has not disclosed backing from a single-family source or sovereign wealth entity, distinguishing it from privately capitalized family office biotech ventures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: